

Rx

For the use of Registered Medical Practitioner or a Hospital or a Laboratory only

Nicorandil for Injection 48 mg

AMERICAN ANGEDIL 48 Injection

Lyophilized Single Dose Vial
For Intravenous Infusion only
Sterile & Nonpyrogenic

1. Composition

Each vial contains:
Nicorandil I.P.48 mg
Excipients.....q.s.

2. Dosage Form and Strength

Nicorandil is supplied in glass vials containing sterile lyophilized powder equivalent 48 mg of Nicorandil.

3. Clinical Particulars

3.1 Indication

For the prevention and long term treatment of angina pectoris.

3.2 Posology and Method of Administration

For intravenous infusion only (Sterile & Nonpyrogenic)

Do not use the vial if the reconstituted solution is not clear or shows any particulate matter

The usual adult starting dosage for intravenous drip infusion is 2 mg of nicorandil per hour. The dose may be adjusted depending on the symptoms and must not exceed 6 mg per hour. The contents of Nicorandil injection vial are to be dissolved in physiological saline or 5% glucose solution for injection to yield a 0.01-0.03% solution and should be used within 24 hours of preparation. Nicorandil I.V. should not be simultaneously administered through same line with other I.V. solutions.

Instructions for dilutions

Vial Strength	No. of Vials	Volume of Diluent (NS or 5% Dextrose to be added in vial for reconstitution)	Final volume to be made with diluent (NS or 5% Dextrose)	% Solution Prepared	Min Speed of Admin	Max Speed of Admin
48 mg	1	20 ml	250 ml	0.019% 0.19 mg/ml	250 ml/ 24 hr	250 ml/ 8 hr
48 mg	2	20 ml	500 ml	0.019% 0.19 mg/ml	500 ml/ 24 hr	500 ml/ 8 hr

3.3 Contraindications

Nicorandil I.V. is contraindicated in patients with serious hepatic or renal dysfunction, cerebral dysfunction, serious hypotension or cardiogenic shock. It is also contraindicated in patients with Eisenmenger's syndrome or primary pulmonary hypertension and in patients with right ventricular infarction. Nicorandil is not recommended in patients with symptoms of dehydration, neurocirculatory asthenia, with closed angle glaucoma and with a history of hypersensitivity to potassium channel openers, nitrates and nitrite derivatives and any excipients of this product.

3.4 Special Warnings and Precautions

While administering Nicorandil injection I.V., blood pressure and hemodynamics should be monitored frequently. Dose adjustment should be done gradually according to patient's hemodynamic status and symptoms. In patients showing hypotension, correction can be made by dose reduction or discontinuation of nicorandil injection I.V. or by administration of a pressor agent.

3.5 Drug Interactions

No pharmacological or pharmacokinetic interactions of nicorandil have been observed in humans or animals with betablockers, digoxin, rifampicin, cimetidine, nicoumalone, calcium antagonist or a combination of digoxin and frusemide. Nevertheless, there is the possibility that nicorandil may potentiate the blood pressure lowering effect of other vasodilators, tricyclic antidepressants or alcohol.

3.6 Use in Special Population

Safety of Nicorandil has not been studied in pregnant women. Therefore, it is advisable not to administer nicorandil to pregnant women or women having possibilities of being pregnant.

As it is not known whether nicorandil is excreted in human milk, breast feeding should be avoided by nursing mothers who require therapy. Safety of nicorandil in children has not been established (no clinical experience).

3.7 Effects on ability to drive and use machines

NA

3.8 Undesirable effects

Following adverse reactions have been reported infrequently with Nicorandil injection I.V.

1. Cardiovascular: Decrease in blood pressure, Increase in heart rate.
2. Psychoneurologic: Headache, light-headed feeling, numbness of limbs.
3. Gastrointestinal: Nausea, vomiting, upper abdominal discomfort.
4. Hepatic: Elevation of SGOT, SGPT and total bilirubin.
5. Hematologic: Anemia

3.9 Overdose

Acute overdosage is likely to be associated with peripheral vasodilation, hypotension and reflex tachycardia. Cardiac function should be monitored and general supportive measures should be employed. If necessary, circulating plasma volume should be increased by infusion of plasma expanders. In life threatening situations administration of vasopressors should be considered.

4. Pharmacological Properties

4.1 Pharmacodynamic Properties

Nicorandil is a new antianginal drug having potent vasodilator and antispasmodic properties, which are relatively selective to the coronary arteries. Nicorandil is a potassium channel opener that also contains a nitrate moiety. Potassium channel opening hyperpolarizes vascular cell membranes, causing voltage operated calcium (Ca⁺⁺) ion channels to close with a consequent reduction in free intracellular Ca⁺⁺ concentration that results in a reduction in vasomotor tone, particularly in the coronary resistance vessels. Nicorandil also induces vascular smooth muscle relaxation by releasing Nitric oxide (NO) which in turn increases intracellular cyclic guanosine monophosphate (cGMP) levels. Nicorandil markedly increases coronary blood flow in a dose dependent manner and has little effect on cardiac output, arterial pressure and pulse pressure. Nicorandil thus dilates the large coronary arteries to the same extent as nitroglycerine through NO release and reduces the vasomotor tone of the resistant coronary vessels through its potassium channel opener action. In non-ischemic myocardium, Nicorandil at therapeutic doses has neither negative inotropic effect nor any effect on atrioventricular conduction. The overall action improves blood flow to post-stenotic regions and the oxygen balance in the myocardium. Furthermore, increasing clinical evidence suggests that potassium channel activation exerts a direct cytoprotective effect by augmenting normal physiological processes which protects the heart against ischemic events mimicking the action of Adenosine. Intravenous nicorandil (4-12 mg) has been shown to produce an 8-27% increase in the diameter of the major coronary arteries and 9-53% decrease in coronary vascular resistance in patients with coronary artery disease. The effect of intravenous nicorandil was dose dependent and was greater in the coronary arteries of patients with variant angina pectoris. Intravenous nicorandil was found to produce an increase in coronary sinus blood flow of between 6 and 81 % in contrast to nitroglycerine and isosorbide nitrate, which decreased blood flow. Coronary vascular resistance was reduced by 9 to 53% after a single intravenous dose of Nicorandil. Nicorandil was found to decrease the frequency of chest pain attack rate and complete suppression of chest pain was achieved in 75% of those treated with Nicorandil. A single intravenous dose of nicorandil 4 to 12 mg was found to produce a significant decrease in mean arterial pressure (5 to 15%), systemic vascular resistance (8 to 27%), pulmonary capillary wedge pressure (15 to 41%) and left ventricular end diastolic pressure (8 to 18%) in patients with coronary artery disease, myocardial infarction or congestive heart failure as well as in healthy subjects. Cardiac index and stroke index remained unchanged after Nicorandil administration. A double-blind controlled clinical study in patients with unstable angina demonstrated significant usefulness of Nicorandil injection I.V. Global clinical improvement rates of 68.4 to 75.0% have been reported in clinical studies including double-blind trials with a total of 134 assessable patients with unstable angina.

4.2 Pharmacokinetic properties

Nicorandil Injection I.V. when administered by intravenous infusion at a rate of 2, 4 or 6 mg/hour for 6 hours, reached a steady state plasma concentration between 3 and 6 hours after the initial infusion followed by a biphasic elimination with a half-life (T_{1/2} (β) of 1.56, 1.98 and 1.32 hours, respectively. When a single 2 mg intravenous dose of Nicorandil injection I.V. was administered to five healthy volunteers, the half-life (T_{1/2}) was 0.11 hour, the area under the plasma concentration time curve (AUC) was 16.2 ng.hour/mL, and the total clearance (C_ltotal) was 126 L/hour.


5. Non-Clinical Properties

5.1 Animal Toxicology/Pharmacology

NA

6. Description

Nicorandil is a vasodilatory drug that functions through potassium channels and intracellular cGMP concentrations commonly used to treat angina. The chemical structure is:



7. Pharmaceutical Particulars

7.1 Incompatibilities

NA

7.2 Shelf Life: Refer Pack.

7.3 Package Information: 1 vial packed in a carton along with leaflet.

7.4 Storage and Handling Instructions: Store at 2°C -8°C. Do not Freeze. Keep the medicine out of reach of children.

Marketed by:

AMERICAN REMEDIES
Care & Cure with Research
American Remedies Healthcare Pvt. Ltd.
(An ISO 9001:2015 Certified Company)

Gala No. 105 to 111, 1st Flr., Bldg. No. E-15/A,
Harihar Complex, Bhiwandi, Mumbai - 421302
E-mail: info@americanremedies.in
ICO: American Remedies LLC, DE, USA
© Copyright

Scan for
Batch Certificate

